Status:
COMPLETED
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
Lead Sponsor:
Zhejiang University
Conditions:
Idiopathic Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs. In addition, clinical studies suggest th...
Eligibility Criteria
Inclusion
- Clinical diagnosis of idiopathic pulmonary arterial hypertension
- in New York Heart Association (NYHA) functional class II to III
- a mean pulmonary artery pressure more than 30 mmHg on right heart catheterization
- the ability to walk ≥50 m during a standardized 6-minute walk test.
Exclusion
- Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, NYHA functional class IV, major bleeding requiring blood transfusion, diabetes, renal dysfunction, and evidence for malignant diseases were excluded
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00257413
Last Update
November 22 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, the First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310003